Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"GliaPharm","sponsor":"Wyss Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by GliaPharm

    Menu

    GliaPharm

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              GliaPharm

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease

              Details:

              The company is currently tackling hypometabolism in an ‘orphan’ neurological disease named Glucose Transporter 1-Deficiency Syndrome. This rare disease is characterized by a reduced entry of glucose into the brain that leads to severe symptoms in children and adults.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Wyss Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY